[1] Zhang R, Baunoch D, De Groot LJ. Genetic immunotherapy for medullary thyroid carcinoma:destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murineinterleukin-2 gene[J]. Thyroid, 1998, 8(12):1137-1146.
[2] Zhang R, Straus FH, De Groot LJ. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin-2:dissemination and cytotoxicity studies in a rat tumor model[J]. Endocrinology, 1999, 140(5):2152-2158.
[3] Zhang R, De Groot LJ. Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12(mIL12) subunits in a rat medullary thyroid carcinoma model[J]. Clin Endocrinol (Oxt), 2000, 52(6):687-694.
[4] Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12[J]. Gene Ther, 2002, 9(1):64-74.
[5] Soler MN, Bobe P, Benihoud K, et al. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase Ⅱ DNA injection[J]. J Gene Med, 2000, 2(5):344-352.
[6] Nishihara E, Nagayama Y, Mawatari F, et al. Retrovirusmediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo[J]. Endocrinology, 1997, 138(11):4577-4583.
[7] Braiden V, Nagayama Y, Iitaka M, et al. Retroviras-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter[J]. Endocrinology, 1998, 139(9):3996-3999.
[8] Nagayama Y, Nishihara E, Iitaka M, et al. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system[J]. Cancer Res, 1999, 59(13):3049-3052.
[9] Shimura H, Suzuki H, Miyazaki A, et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells[J]. Cancer Res, 2001, 61(9):3640-3646.
[10] Kitazono M, Chuman Y, Aikou T, et al. Adenovirus HSVTK construct with thyroid-specific promoter:Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway[J]. Int J Cancer, 2002, 99(3):453-459.
[11] Zhang R, De Groot LJ. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model:relationship of bystander effect and antitumor efficacy[J]. Thyroid, 2000, 10(4):313-319.
[12] Zhang R, De Groot LJ. An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma[J]. Endocr Relat Cancer, 2001, 8(4):315-325.
[13] Narimatsu M, Nagayama Y, Akino K, et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line[J]. J Clin Endocrinol Metab, 1998, 83(10):3668-3672.
[14] Kim SB, Ahn IM, Park HI, et al. Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene[J]. Head Neck, 2001, 23(3):223-229.
[15] Nagayama Y, Shigematsu K, Namba H, et al. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo[J]. Anticancer Res, 2000, 20(4):2723-2728.
[16] Nikitin AY, Juarez-Percz MI, Li S, et al. Rb-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/-mice[J]. Proc Natl Acad Sci USA, 1999, 96:3916-3921.
[17] Moretti F, Nanni S, Farsetti A, et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status[J]. J Clin Endocrinol Metab, 2000, 85(1):302-308.
[18] Caillou B, Troalen F, Baudin E, et al. Na+/I- symporter distribution in human thyroid tissues:an immunohistochemical study[J]. J Clin Endocrinol Metab, 1998, 83(11):4102-4106.
[19] Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipepfide(FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells[J]. J Clin Endocrinol Metab, 2001, 86(7):3430-3435.
[20] Cerutti J, Trapasso F, Battaglia C, et al. Block of c-myc expression by anfisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines[J]. Clin Cancer Res, 1996, 2:119-126.
[21] Hanpt K, Siegel F, Lu M, et al. Induction of a cellular and humoral immune response against the tumor associated antigen calcitonin by genetic immunization[J]. J Endocrinol Invest, 1999, 22(suppl):4.
[22] Schmutzler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer[J]. Eur J Endocrinol, 2000, 143(1):15-24.
[23] De Groot LJ, Zhang R. Clinical review 131-:Gene therapy for thyroid cancer:where do we stand?[J]. J Clin Endocrinol Metab, 2001, 86(7):2923-2928.